UK Singer Joe Longthorne is Back Performing

British singer Joe Longthorne is back performing this weekend after a one year absence from the stage through illness that left him fighting for his life. The star spent months in the hospital after setbacks following a bone marrow transplant at Manchester Royal Infirmary. The singer was first diagnosed with non-Hodgkin's lymphoma(NHL) in 1989. He believed he had been given the all-clear in 1997, but the cancer returned.



His official website said the 50-year-old, who has fought NHL for years, has been "feeling much stronger and with every day that passes a little more excited that he will be performing again". He will be performing at the Grand Theatre, Blackpool, Easter Day for the first night of his 2006 UK tour, in what should prove a special and emotional night for his many loyal fans. The tour includes several Yorkshire venues, Sheffield and Bradford in May, Leeds in June and finally his home city in July.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap